Paris, January 13th, 2015 – MedDay, a biotechnology company focused on the treatment of nervous system disorders, today announced the appointment of Philippe Goupit as an independent Non-Executive Director. Mr. Goupit was, until recently, Vice President, Corporate Licenses at Sanofi. He will bring to MedDay’s Board his significant business and corporate development experience covering the biotechnology and pharmaceuticals sector.
Mr. Goupit has more than 30 years’ experience in the pharmaceuticals industry and has spent over 20 years at Sanofi. His experience in business development covers M&A, as a former head of the corporate M&A group in Sanofi, and licensing activities. Philippe Goupit also served for some years as the Head of Investor Relations at Sanofi.
Commenting on Philippe’s appointment, Frédéric Sedel, Chief Executive Officer of MedDay, said: “Philippe’s broad experience will be hugely beneficial to MedDay as the Company continues to develop its pipeline of assets which address areas of unmet need in neurological and psychiatric diseases, through brain metabolism. Through his experience Philippe will contribute to MedDay’s corporate and business development strategy.”
Philippe Goupit, commented: “I am delighted to be joining the Board of MedDay to help it in the next steps of its corporate development. I strongly believe that MedDay’s product pipeline and its research platform, SPECMET, could have a major impact on the treatment of neurological and psychiatric diseases.”
MedDay is a biotechnology company developing new drugs for nervous system disorders. The company was founded in 2011 by Frédéric Sedel, MD, PhD (Chief Executive Officer), a leading neurologist and neuroscientist; and Guillaume Brion, MD (Chief Operating Officer) who has 25 years of experience in drug development and clinical research in the pharmaceutical industry. In April 2013, InnoBio, a biotechnology fund managed by BPIFrance, and Sofinnova Partners together invested a total of €8 million in MedDay. The Company’s most advanced pipeline candidate is MD1003 for the treatment of primary and secondary progressive multiple sclerosis. MD1003 is currently being investigated in 2 pivotal phase III studies in France, involving 250 patients. The first patient was included in October 2013 and the Company expects to announce the data from the MD1003 studies in 2015.
For more information, please contact:
Frédéric Sedel, Chief Executive Officer
Consilium Strategic Communications
Mary-Jane Elliott, Jonathan Birt, Ivar Milligan, Laura Thornton
Tel: +44 (0)20 3709 5700